BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company's core business model revolves around advancing its pipeline of immunotherapy candidates through clinical trials with the aim of eventual commercialization. Revenue generation is currently absent, as the company is in the development stage, and its primary customer segments would be cancer patients, particularly those with metastatic breast cancer and, in the future, prostate cancer. The company relies on a combination of internal research and development, and collaborations with third-party contract research organizations and manufacturers for its operations.

The company's lead product candidate is Bria-IMT™, a whole-cell immunotherapy for metastatic breast cancer. This therapy is currently in a pivotal Phase 3 study (NCT06072612) in combination with an immune checkpoint inhibitor (Retifanlimab). Bria-IMT™ has received Fast Track Designation from the U.S. FDA, which is intended to expedite the review process for treatments addressing unmet medical needs. In its Phase 2 study, Bria-IMT™ in combination with an immune checkpoint inhibitor demonstrated a median overall survival of 13.4 months ¹ for all patients, and 16.5 months ² for patients treated since 2022 with the Phase 3 formulation. This compares favorably to reported literature benchmarks of 6.7-9.8 months ³ for similar patients. The therapy has shown promising results in HR+ metastatic breast cancer patients with a median overall survival of 17.3 months ⁴, exceeding TRODELVY® (14.4 months ⁵) and chemotherapy (11.3 months ⁶). In triple-negative breast cancer (TNBC), Bria-IMT™ plus CPI showed a median overall survival of 13.9 months ⁷, also surpassing TRODELVY® (11.8 months ⁸) and chemotherapy (6.9 months ⁹). The intracranial overall response rate (iORR) for patients with intracranial metastatic disease was 71% ¹⁰, which is significantly higher than the typical iORR of less than 20% ¹¹ seen in comparable patients.

Another significant product in the pipeline is Bria-OTS™, a personalized off-the-shelf immunotherapy, also known as Bria-BRES™, for metastatic breast cancer, which is currently in an ongoing Phase 1/2 study (NCT06471673). Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines, aiming to provide matched treatment to over 99% ¹² of patients. The first patient treated with Bria-OTS™ monotherapy achieved complete resolution of a lung metastasis, which was sustained at the 6-month timepoint. The company is also developing enhanced versions, Bria-OTS+™, for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), as well as breast cancer (Bria-BRES+™). In September 2024, BriaCell received positive feedback from its Pre-IND meeting with the FDA for Bria-PROS+™ for prostate cancer, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies.

BriaPro Therapeutics Corp., a majority-owned subsidiary of BriaCell, is developing high-affinity antibodies targeting B7-H3, an immune checkpoint molecule, for incorporation into its proprietary Bria-TILsRx™ platform. This platform is designed to activate tumor-infiltrating lymphocytes within the tumor microenvironment and utilize multivalent technology for simultaneous engagement of multiple cancer-associated and immune pathway targets. BriaCell has also secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment.

For the fiscal year ended July 31, 2025, BriaCell reported a net loss of $26,311,867 ¹³, compared to a net loss of $4,791,466 ¹⁴ in the prior fiscal year. The accumulated deficit as of July 31, 2025, was $111,755,564 ¹⁵, an increase from $85,443,697 ¹⁶ as of July 31, 2024. Total research, development, and clinical trial costs decreased to $21,270,678 ¹⁷ in 2025 from $27,177,807 ¹⁸ in 2024. General and administrative expenses were $5,934,125 ¹⁹ in 2025, compared to $6,152,269 ²⁰ in 2024. Financial income, net, was $114,511 ²¹ in 2025, a decrease from $262,566 ²² in 2024, primarily due to lower interest income of $176,431 ²³ in 2025 compared to $288,018 ²⁴ in 2024, and the recognition of $36,979 ²⁵ in interest expense in 2025. The change in fair value of the warrant liability resulted in a gain of $758,364 ²⁶ in 2025, significantly lower than the $28,242,472 ²⁷ gain in 2024. Diluted net loss per share was $62.19 ²⁸ in 2025, compared to $43.68 ²⁹ in 2024. The company had cash and cash equivalents of $10,493,808 ³⁰ as of July 31, 2025, up from $862,089 ³¹ in 2024. Total current assets were $19,926,576 ³² and total current liabilities were $3,977,988 ³³, resulting in a positive working capital of $15,948,588 ³⁴ as of July 31, 2025, compared to a negative working capital of $3,807,303 ³⁵ in 2024.

Year-over-year, research, development, and clinical trial costs decreased by $5,907,129 ³⁶, primarily due to the conclusion of the Bria-IMT™ Phase 1/2a trial. Clinical trial expenses for the Bria-IMT™ Pivotal Phase 3 study increased from $11,594,463 ³⁷ in 2024 to $13,511,235 ³⁸ in 2025, reflecting the progression of the study. Bria-IMT™ Phase 1/2a costs decreased from $4,239,415 ³⁹ in 2024 to $1,013,828 ⁴⁰ in 2025. Bria-OTS™ Phase 1/2a costs were $428,233 ⁴¹ in 2025, up from $nil ⁴² in 2024, as this trial commenced in August 2024. Wages and salaries in R&D increased from $4,567,307 ⁴³ in 2024 to $5,356,806 ⁴⁴ in 2025. Share-based compensation expenses decreased significantly from $734,986 ⁴⁵ in 2024 to $120,050 ⁴⁶ in 2025. The substantial increase in net loss is mainly attributed to a significantly smaller gain on the fair value of the warrant liability in 2025 compared to 2024.

During the reported fiscal period, BriaCell made several significant operational developments. The pivotal Phase 3 study for Bria-IMT™ plus CPI in metastatic breast cancer has consented over 100 ⁴⁷ and enrolled over 75 ⁴⁸ patients as of April 22, 2025. The Data Safety Monitoring Board (DSMB) completed its first, second, and third reviews of safety events on December 2, 2024, March 20, 2025, and June 24, 2025, respectively, recommending continuation of the study with no safety concerns. On April 30, 2025, BriaCell reported "Late-Breaker" Phase 3 data at AACR 2025, identifying potential predictive biomarkers for treatment response. The Bria-OTS™ Phase 1/2 study dosed its first patient on November 21, 2024, and subsequently reported a clinical response with complete resolution of a lung metastasis on February 3, 2025, which was confirmed at 4 months and 6 months follow-up. On May 27, 2025, the Bria-OTS Phase 1/2 Study cleared safety evaluation, transitioning to combination dosing with an immune checkpoint inhibitor. BriaPro Therapeutics Corp., a majority-owned subsidiary, announced a new initiative in antibody therapeutics on April 10, 2025, developing high-affinity antibodies against B7-H3, and filed a patent application for its immuno-oncology platform with novel multitargeting agents on July 29, 2025. The company completed several financings during the fiscal year, raising approximately $50.9 million ⁴⁹ in gross proceeds. Two reverse stock splits were effected: a 1-for-15 split on January 24, 2025, and a 1-for-10 split on August 25, 2025.

BriaCell anticipates reporting top-line data for its pivotal Phase 3 clinical study of Bria-IMT™ as early as H1-2026 ⁵⁰. The successful completion of this pivotal study, with overall survival as the primary endpoint, could lead to full FDA approval of the Bria-IMT™ immune checkpoint inhibitor combination in advanced metastatic breast cancer. The FDA has agreed that an improvement in overall survival in the Bria-IMT™ combination arm compared to the physician's choice of treatment arm will be the primary endpoint. The study is expected to enroll 177 patients ⁵¹ in the Bria-IMT™ combination therapy arm and 177 patients ⁵² in the treatment of physician's choice arm, with an additional 50 patients ⁵³ in the Bria-IMT™ regimen alone arm for additional information, who will not be included in the primary analysis. An interim evaluation for efficacy will occur at 144 events (mortalities) ⁵⁴; if the hazard ratio (HR) is ≤ 0.6 ⁵⁵, BriaCell will submit a Biologics Licensing Application (BLA). If the HR is > 0.6 ⁵⁶, the study will continue to completion with an HR target of 0.7 ⁵⁷.

The company's growth areas include the continued development of Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for various cancer types, including prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), in addition to breast cancer (Bria-BRES+™). The positive Pre-IND meeting with the FDA for Bria-PROS+™ in September 2024, where the FDA waived requirements for animal toxicology and pharmacokinetic studies, is expected to simplify the development pathway and accelerate the clinical timeline for this candidate. IND filings for these immunotherapy cell lines are anticipated to begin in late 2025 or early 2026 ⁵⁸. Furthermore, BriaPro Therapeutics Corp., a majority-owned subsidiary, is developing high-affinity antibodies against B7-H3 for its Bria-TILsRx™ platform, with human clinical studies expected to be initiated in the first half of 2025 ⁵⁹. BriaPro also plans to optimize its proprietary protein kinase C delta inhibitors and advance them to the candidate selection stage, with human clinical studies expected to be initiated in the second half of 2025 ⁶⁰.

Operationally, the company expects operating expenses and staffing levels to increase in the future as it advances its clinical programs, scales its operations, and undertakes activities to support potential commercialization. Managing this growth will require attracting, retaining, training, and motivating additional qualified personnel and improving operational, financial, and management information systems. The company will also need to effectively manage multiple, interdependent relationships with third-party contract research organizations, contract manufacturers, clinical investigators, regulatory authorities, academic collaborators, and suppliers.

For planned capital allocation, the company incurred $21,270,678 ⁶¹ in research and development expenses for the year ended July 31, 2025. Cash used in investing activities for the year ended July 31, 2025, was $7,646,000 ⁶², primarily related to the purchase of short-term investments ($7,316,000 ⁶³) and an equity investment in BC Therapeutics ($330,000 ⁶⁴). The company intends to raise additional capital through debt or equity financings to achieve its business plan objectives.

The company explicitly flagged several structural headwinds and execution risks. There is substantial doubt about its ability to continue as a going concern, given recurring losses and an accumulated deficit of $111,755,564 ⁶⁵ as of July 31, 2025. The company's continuation is dependent on generating positive cash flows and securing additional financing, which is not assured. The company is a pre-revenue clinical stage company, and anticipated growth will place significant strain on managerial, operational, financial, and technical resources. The market for its product candidates is unproven, and there is no assurance that products will be successfully developed, commercialized, or generate significant revenues. The company is heavily reliant on third parties for manufacturing, pharmaceutical development, and marketing, and any failure in these relationships could adversely affect its business. Geopolitical developments and international conflicts, such as instability or war in the Middle East, the ongoing conflict between Russia and Ukraine, or a deterioration in relations between the United States and China, may contribute to global uncertainty, disrupt financial and commodity markets, and adversely affect investor risk appetite. These events may impair the company's ability to source key raw materials, reagents, or specialized components, potentially leading to increased costs, delays, or operational interruptions. The company may also be adversely affected by the effects of inflation, which could increase its overall cost structure.

BriaCell faces significant risks, including substantial doubt about its ability to continue as a going concern, evidenced by recurring losses of $26,311,867 ⁶⁶ in fiscal year 2025 and an accumulated deficit of $111,755,564 ⁶⁷ as of July 31, 2025. The company is heavily reliant on third parties for manufacturing, pharmaceutical development, and marketing, and any failure in these contractual duties or regulatory obligations could delay or terminate clinical trials and commercialization efforts. Pre-clinical studies and initial clinical trials are not necessarily predictive of future results, and favorable outcomes in early trials may not be replicated in later, larger studies, potentially leading to delays or termination of product development. The company is susceptible to intellectual property suits, which could incur substantial costs or prohibit product sales, and its intellectual property protection may be inadequate. Changes in legislation and regulations, including those related to government price controls, reimbursement, and access to drugs, could adversely affect future revenues and profitability. Failure to obtain U.S., Canadian, and/or foreign regulatory approval for product candidates would prevent commercialization. Modifications to approved products may require new regulatory clearances or recalls. The pharmaceutical business is subject to increasing government price controls and other restrictions on pricing, reimbursement, and access to drugs, which could adversely affect future revenues and profitability. United States federal and state privacy laws, and equivalent foreign laws, may increase operating costs and expose the company to civil and criminal sanctions. Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships, and conflicts (e.g., Middle East, Russia-Ukraine) could make it more difficult to access financing and adversely affect business and operations. Inflation also poses a risk by increasing the overall cost structure. The company's common shares could be delisted from Nasdaq if it fails to comply with listing requirements, such as the minimum bid price, especially under the Nasdaq Excessive Reverse Stock Split Rule, which limits eligibility for compliance periods after a reverse stock split.

Management's message to shareholders conveys a tone of active progression in clinical development and strategic diversification, while acknowledging the significant financial challenges inherent in a pre-revenue biotechnology company. They emphasize the advancement of Bria-IMT™ in a pivotal Phase 3 study, with top-line data anticipated as early as H1-2026 ⁶⁸, and highlight the positive safety reviews from the Data Safety Monitoring Board. Management is also focused on the development of Bria-OTS™ and its next-generation variants, Bria-OTS+™, for various cancer types, noting the FDA's waiver of animal toxicology and pharmacokinetic studies for Bria-PROS+™ as a key accelerator. Strategic priorities include the successful completion of the Bria-IMT™ Phase 3 study to achieve full FDA approval, the continued development and anticipated IND filings for Bria-OTS+™ candidates starting in late 2025 or early 2026 ⁶⁹, and the advancement of BriaPro Therapeutics' antibody development program, with human clinical studies expected to be initiated in the first half of 2025 ⁷⁰ for Bria-TILsRx™ and in the second half of 2025 ⁷¹ for PKCδ inhibitors. Despite these advancements, management explicitly states the company has incurred significant losses, including a net loss of $26,311,867 ⁷² for the year ended July 31, 2025, and has an accumulated deficit of $111,755,564 ⁷³, raising substantial doubt about its ability to continue as a going concern, and underscores the ongoing need for additional capital.